Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | MEN1 | O00255 | 4/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 6/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | AHR | P35869 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 6/20 | 0.42 |
| ▸ | HPGD | P15428 | 3/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14583961 | 1.00 | MAPT (0.47) | MAPTALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL13180945 | 0.80 | NPC1 (0.44) | MAPTALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL3088448 | 0.80 | NPC1 (0.44) | MAPTALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL10746855 | 0.77 | MAPT (0.62) | MAPTALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL5694725 | 0.77 | NPSR1 (0.50) | MAPTALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL5694726 | 0.77 | NPSR1 (0.50) | MAPTALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL30769665 | 0.75 | MAPT (0.53) | MAPTALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL2647339 | 0.75 | MAPT (0.53) | MAPTALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL4911670 | 0.74 | MAPT (0.53) | MAPTALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL4911666 | 0.74 | MAPT (0.53) | MAPTALDH1A1MEN1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1919908-B1 | TRIAZOLE DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | GLAXO GROUP LTD (GB) | 2010-11-10 | — | — | EP | disclosed |
| US-7799815-B2 | Triazole derivatives as modulators of dopamine D3 receptors | GLAXO GROUP LIMITED (GB) | 2010-09-21 | — | — | US | disclosed |
| US-7799815-B2 | Triazole derivatives as modulators of dopamine D3 receptors | GLAXO GROUP LIMITED (GB) | 2010-09-21 | — | — | US | disclosed |
| US-20090221593-A1 | TRIAZOLE DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | GLAXO GROUP LIMITED (GB) | 2009-09-03 | — | — | US | disclosed |
| US-20090221593-A1 | TRIAZOLE DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | GLAXO GROUP LIMITED (GB) | 2009-09-03 | — | — | US | disclosed |
| EP-1919908-A1 | TRIAZOLE DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | GLAXO GROUP LIMITED (GB) | 2008-05-14 | — | — | EP | disclosed |
| WO-2007022933-A1 | TRIAZOLE DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | GLAXO GROUP LIMITED (GB) | 2007-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221593-A1 | TRIAZOLE DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | DRD3, HTR5A, HTR3C | MAPT 3151/4885ALDH1A1 2304/4885MEN1 4807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.